Down-regulation of caveolin-1, a candidate tumor suppressor gene, in sarcomas

被引:157
作者
Wiechen, K
Sers, C
Agoulnik, A
Arlt, K
Dietel, M
Schlag, PM
Schneider, U
机构
[1] Humboldt Univ, Fak Med, Univ Klinikum Charite, Inst Pathol, D-10117 Berlin, Germany
[2] Robert Rossle Klin, Clin Surg & Surg Oncol, D-13122 Berlin, Germany
[3] Baylor Coll Med, Dept Obstet & Gynecol, Houston, TX 77030 USA
关键词
D O I
10.1016/S0002-9440(10)64031-X
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Caveolae are plasma membrane microdomains that have been implicated in the regulation of several intracellular signaling pathways. Previous studies suggest that caveolin-1, the main structural protein of caveolae, could function as a tumor suppressor. Caveolin-1 is highly expressed in terminally differentiated mesenchymal cells including adipocytes, endothelial cells, and smooth muscle cells. To study whether caveolin-1 is a possible tumor suppressor in human mesenchymal tumors, we have analyzed the expression using immunohistochemistry in normal mesenchymal tissues, 22 benign and 79 malignant mesenchymal tumors. Caveolin-1 was found to be expressed in fibromatoses, leiomyomas, hemangiomas, and lipomas at high levels comparable to normal mesenchymal tissues. The expression of caveolin-1 was slightly reduced in four of six well-differentiated liposarcomas and strongly reduced or lost in three of three fibrosarcomas, 17 of 20 leiomyosarcomas, 16 of 16 myxoid/round cell/pleomorphic liposarcomas, five of eight angiosarcomas, 15 of 18 malignant fibrous histiocytomas, and eight of eight synovial sarcomas. The immunohistochemical findings were confirmed by Western blot analysis in a number of tumors. High levels of both the 24-kd [alpha]- and the 21-kd [beta]-isoform of caveolin-1 were detected in the nontumorigenic human fibroblast cell line IMR-90. In contrast, in HT-1080 human fibrosarcoma cells, caveolin-1 is strongly down-regulated. We show that the [alpha]-isoform of caveolin-1 is potently up-regulated in HT-1080 cells by inhibition of the mitogen-activated protein kinase-signaling pathway with the specific inhibitor PD 98059, whereas the specific inhibitor of DNA methylation 5-aza-2'-deoxycytidine only marginally up-regulates caveolin-1. In addition, re-expression of caveolin-1 in HT-1080 fibrosarcoma cells potently inhibited colony formation. From these we conclude that caveolin-1 is likely to act as a tumor suppressor gene in human sarcomas.
引用
收藏
页码:833 / 839
页数:7
相关论文
共 29 条
[1]   Sequence and detailed organization of the human caveolin-1 and -2 genes located near the D7S522 locus (7q31.1) -: Methylation of a CpG island in the 5′ promoter region of the caveolin-1 gene in human breast cancer cell lines [J].
Engelman, JA ;
Zhang, XL ;
Lisanti, MP .
FEBS LETTERS, 1999, 448 (2-3) :221-230
[2]   Genes encoding human caveolin-1 and -2 are co-localized to the D7S522 locus (7q31.1), a known fragile site (FRA7G) that is frequently deleted in human cancers [J].
Engelman, JA ;
Zhang, XL ;
Lisanti, MP .
FEBS LETTERS, 1998, 436 (03) :403-410
[3]   Recombinant expression of caveolin-1 in oncogenically transformed cells abrogates anchorage-independent growth [J].
Engelman, JA ;
Wykoff, CC ;
Yasuhara, S ;
Song, KS ;
Okamoto, T ;
Lisanti, MP .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (26) :16374-16381
[4]   p42/44 MAP kinase-dependent and -independent signaling pathways regulate caveolin-1 gene expression - Activation of Ras-MAP kinase and protein kinase A signaling cascades transcriptionally down-regulates caveolin-1 promoter activity [J].
Engelman, JA ;
Zhang, XL ;
Razani, B ;
Pestell, RG ;
Lisanti, MP .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (45) :32333-32341
[5]  
ENZINGER FM, 1994, SOFT TISSUE TUMORS
[6]   Targeted downregulation of caveolin-1 is sufficient to drive cell transformation and hyperactivate the p42/44 MAP kinase cascade [J].
Galbiati, F ;
Volonté, D ;
Engelman, JA ;
Watanabe, G ;
Burk, R ;
Pestell, RG ;
Lisanti, MP .
EMBO JOURNAL, 1998, 17 (22) :6633-6648
[7]   β-catenin expression pattern in stage I and II ovarian carcinomas -: Relationship with β-catenin gene mutations, clinicopathological features, and clinical outcome [J].
Gamallo, C ;
Palacios, J ;
Moreno, G ;
de Mora, JC ;
Suárez, A ;
Armas, A .
AMERICAN JOURNAL OF PATHOLOGY, 1999, 155 (02) :527-536
[8]  
GLENNEY JR, 1989, J BIOL CHEM, V264, P20163
[9]   Analysis of the CAVEOLIN-1 gene at human chromosome 7q31.1 in primary tumours and tumour-derived cell lines [J].
Hurlstone, AFL ;
Reid, G ;
Reeves, JR ;
Fraser, J ;
Strathdee, G ;
Rahilly, M ;
Parkinson, EK ;
Black, DM .
ONCOGENE, 1999, 18 (10) :1881-1890
[10]  
Jenkins RB, 1998, CANCER RES, V58, P759